Camp4 Therapeutics (CAMP) Cash & Equivalents (2023 - 2026)

Camp4 Therapeutics has disclosed Cash & Equivalents across 4 years of filings, most recently posting $99.2 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $99.2 million, up 101.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $99.2 million (up 101.24% YoY), and the FY2025 annual result was $109.5 million, up 71.02% from the prior year.
• Cash & Equivalents came in at $99.2 million for Q1 2026 at Camp4 Therapeutics, down from $109.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $109.5 million in Q4 2025 to a low of $2.5 million in Q3 2024.
• The 4-year median for Cash & Equivalents is $50.5 million (2023), against an average of $58.6 million.
• Across the five-year window, Cash & Equivalents slumped 94.99% in 2024 and jumped 2878.64% in 2025, its largest moves.
• Camp4 Therapeutics' Cash & Equivalents stood at $38.4 million in 2023, then surged by 66.86% to $64.0 million in 2024, then jumped by 71.02% to $109.5 million in 2025, then fell by 9.41% to $99.2 million in 2026.
• The last three Cash & Equivalents figures came in at $99.2 million (Q1 2026), $109.5 million (Q4 2025), and $75.3 million (Q3 2025), per Business Quant data.